IL232466A - Preparations and Methods for Prostate Cancer Analysis - Google Patents

Preparations and Methods for Prostate Cancer Analysis

Info

Publication number
IL232466A
IL232466A IL232466A IL23246614A IL232466A IL 232466 A IL232466 A IL 232466A IL 232466 A IL232466 A IL 232466A IL 23246614 A IL23246614 A IL 23246614A IL 232466 A IL232466 A IL 232466A
Authority
IL
Israel
Prior art keywords
compositions
methods
prostate cancer
cancer analysis
analysis
Prior art date
Application number
IL232466A
Other languages
English (en)
Hebrew (he)
Other versions
IL232466A0 (en
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL232466A0 publication Critical patent/IL232466A0/en
Publication of IL232466A publication Critical patent/IL232466A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y116/00—Oxidoreductases oxidizing metal ions (1.16)
    • C12Y116/01—Oxidoreductases oxidizing metal ions (1.16) with NAD+ or NADP+ as acceptor (1.16.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90287—Oxidoreductases (1.) oxidising metal ions (1.16)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4915—Blood using flow cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
IL232466A 2011-11-29 2014-05-05 Preparations and Methods for Prostate Cancer Analysis IL232466A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161629886P 2011-11-29 2011-11-29
US201261703099P 2012-09-19 2012-09-19
PCT/US2012/066998 WO2013082249A2 (en) 2011-11-29 2012-11-29 Compositions and methods for prostate cancer analysis

Publications (2)

Publication Number Publication Date
IL232466A0 IL232466A0 (en) 2014-06-30
IL232466A true IL232466A (en) 2017-10-31

Family

ID=47324459

Family Applications (1)

Application Number Title Priority Date Filing Date
IL232466A IL232466A (en) 2011-11-29 2014-05-05 Preparations and Methods for Prostate Cancer Analysis

Country Status (15)

Country Link
US (2) US20130143237A1 (enExample)
EP (1) EP2786151B1 (enExample)
JP (1) JP6219304B2 (enExample)
KR (1) KR101951514B1 (enExample)
CN (1) CN104067127A (enExample)
AR (1) AR089028A1 (enExample)
AU (1) AU2012345926A1 (enExample)
BR (1) BR112014012882A2 (enExample)
CA (1) CA2854042A1 (enExample)
IL (1) IL232466A (enExample)
MX (1) MX350807B (enExample)
RU (1) RU2641968C2 (enExample)
SG (1) SG11201402711SA (enExample)
WO (1) WO2013082249A2 (enExample)
ZA (1) ZA201403110B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2530505B2 (ja) 1990-03-20 1996-09-04 三ツ星ベルト株式会社 自着層付き防水シ―トの製造法
CN105646661A (zh) * 2014-03-24 2016-06-08 朱育盼 特异性结合前列腺癌的短肽pcp2及其应用
JP6815331B2 (ja) * 2015-04-21 2021-01-20 ジェネンテック， インコーポレイテッド 前立腺がんの分析のための組成物及び方法
PE20200010A1 (es) 2017-04-03 2020-01-06 Hoffmann La Roche Anticuerpos que se unen a steap-1
CN108179134B (zh) * 2017-12-27 2020-11-24 武汉大学 基于EpCAM/PSMA双抗体功能化微流控芯片及其制备方法和应用
FI3817770T3 (fi) 2018-07-02 2026-07-06 Amgen Inc Antigeeniä sitova anti-steap1-proteiini
CN114929743B (zh) * 2019-09-05 2026-01-02 纪念斯隆凯特琳癌症中心 抗steap1抗体及其用途
BR102020013625A2 (pt) * 2020-07-02 2022-01-11 Universidade Federal de Uberlândia Aptâmero modificado, sistema aptaimunológico, painel aptaimunológico, kit, método e uso no diagnóstico de câncer de próstata

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5597531A (en) 1985-10-04 1997-01-28 Immunivest Corporation Resuspendable coated magnetic particles and stable magnetic particle suspensions
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5698271A (en) 1989-08-22 1997-12-16 Immunivest Corporation Methods for the manufacture of magnetically responsive particles
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6046048A (en) * 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO1999041613A1 (en) 1998-02-12 1999-08-19 Immunivest Methods and reagents for the rapid and efficient isolation of circulating cancer cells
US6200765B1 (en) * 1998-05-04 2001-03-13 Pacific Northwest Cancer Foundation Non-invasive methods to detect prostate cancer
DE69941187D1 (de) 1998-06-01 2009-09-10 Agensys Inc Serpentintransmembranantigene exprimiert in menschlichem krebs und deren verwendungen
IL129299A0 (en) * 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
BR0207290A (pt) 2001-02-16 2005-06-07 Immunivest Corp Método para analisar um paciente quanto à presença de uma malignidade, célula maligna isolada das células cultivadas, vacina de tumor, molécula associada com diátese de tumor alterada, métodos para determinar alterações em moléculas associadas com diátese de tumor como um meio para predizer a eficácia da terapia, como um meio para analisar dosagem apropriada para terapia, como um meio para monitorar eficácia da terapia, como um meio para analisar progressão de câncer, para realizar uma biópsia de corpo inteiro em um paciente, e para identificar alterações em uma célula de tumor circulante relativamente a células presentes numa massa de tumor in situ, e, kit de teste para analisar uma amostra de paciente quanto à presença de uma célula maligna não-hematopoiética
US20030190602A1 (en) 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
BRPI0418766B8 (pt) * 2004-04-22 2021-05-25 Agensys Inc anticorpo ou seu fragmento, vetor, composição farmacêutica, ensaio e método para detectar a presença de proteína steap-1, bem como método para distribuir um agente citotóxico ou um agente de diagnóstico
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
PT2845866T (pt) 2006-10-27 2017-08-09 Genentech Inc Anticorpos e imunoconjugados e utilizações dos mesmos
CN103233063A (zh) * 2006-11-08 2013-08-07 密歇根大学董事会 前列腺癌标志物spink1及其应用
JP5394246B2 (ja) * 2007-03-30 2014-01-22 ジェネンテック， インコーポレイテッド 抗体及びイムノコンジュゲートとこれらの使用方法
EP2335075A4 (en) * 2008-09-05 2011-12-14 Scripps Research Inst METHOD FOR DETECTING CIRCULATING TUMOR CELLS
JP5975983B2 (ja) * 2010-04-16 2016-08-23 ベリカム ファーマシューティカルズ， インコーポレイテッド 固形腫瘍を処置するための方法

Also Published As

Publication number Publication date
SG11201402711SA (en) 2014-06-27
ZA201403110B (en) 2017-06-28
MX2014006187A (es) 2014-06-23
JP2015507175A (ja) 2015-03-05
AU2012345926A1 (en) 2014-05-29
AR089028A1 (es) 2014-07-23
US9632091B2 (en) 2017-04-25
RU2641968C2 (ru) 2018-01-23
KR20140100544A (ko) 2014-08-14
WO2013082249A3 (en) 2013-10-10
RU2014126358A (ru) 2016-01-27
US20130143237A1 (en) 2013-06-06
KR101951514B1 (ko) 2019-02-22
EP2786151B1 (en) 2019-07-03
WO2013082249A2 (en) 2013-06-06
IL232466A0 (en) 2014-06-30
MX350807B (es) 2017-09-20
CA2854042A1 (en) 2013-06-06
BR112014012882A2 (pt) 2017-06-13
JP6219304B2 (ja) 2017-10-25
CN104067127A (zh) 2014-09-24
US20160274116A1 (en) 2016-09-22
EP2786151A2 (en) 2014-10-08

Similar Documents

Publication Publication Date Title
IL276362A (en) Cancer treatment methods
EP2734207A4 (en) NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROSTATE CANCER
IL227429A0 (en) The components and methods of cancer treatment
IL258740B (en) Combined liposome preparations for cancer treatment
SG10201610251PA (en) Compositions and methods for cancer immunotherapy
PT2925888T (pt) Composições e métodos para tratamento do cancro
ZA201300567B (en) Methods and compositions for liver cancer therapy
SG10201500124VA (en) Methods and Compositions for Treating Cancer
GB2513732B (en) Methods and compositions for sample identification
GB201302520D0 (en) Compositions and methods for detecting cancer metastasis
EP2768983A4 (en) METHODS OF IDENTIFYING MUTATIONS ASSOCIATED WITH DISEASES
IL228644A0 (en) Cancer treatment methods
ZA201403110B (en) Compositions and methods for prostate cancer analysis
EP2852602A4 (en) COMPOSITIONS AND METHODS FOR CONJUGATING OLIGONUCLEOTIDES
GB201012590D0 (en) Methods for diagnosing cancer
IL226247A0 (en) Cancer treatment methods
EP2640390A4 (en) METHODS OF TREATING CANCER
IL229231A0 (en) Preparations and methods for the treatment of cancer
ZA201502595B (en) Therapeutic methods
SG11201400976WA (en) Methods and pharmaceutical compositions for treating cancer
EP2798327A4 (en) COMPOSITIONS AND METHODS FOR PREPARING SAMPLES
GB201004304D0 (en) Biomarkers for prostate cancer
EP2932273A4 (en) METHODS OF DIAGNOSING AND TREATING PROSTATE CANCER
WO2012106368A9 (en) Methods for inhibiting prostate cancer
IL225959A0 (en) Methods and preparations for diagnosis and treatment @ בסרטן

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees